INTRODUCTION: Current laboratory paradigms of human cocaine administration generally dictate the timing of drug access in ways that may limit assessing aspects of cocaine-taking behavior. Patient-controlled analgesia (PCA) methods, which allow individuals less restricted access to narcotic (i.e., opiate) analgesics, have proven safe and clinically effective for self-regulated treatment of pain. The current study assessed the feasibility, safety, and validity of a model of ad libitum cocaine self-administration, in which participants self-selected the timing of cocaine infusions, using PCA techniques. METHODS: Eight nontreatment seeking, otherwise medically healthy, experienced cocaine users participated in a double-blind, placebo-controlled, escalating-dose regimen of intravenous cocaine (0, 8, 16, and 32 mg per 70 kg) on 4 test days, during which time participants had 2 h of access to cocaine via manual presses of a corded PCA pump button under a fixed ratio 1: time-out 5-min schedule. RESULTS: Procedures were well-tolerated by participants, and no significant adverse events were noted. Measures of cocaine self-administration (e.g., number of responses and interinfusion intervals) indicated a significant main effect of cocaine dose, consistent with predicted dose-response relationships (i.e., decreasing responses and increasing interinfusion intervals with increasing injection dose). Participants appeared to regulate their cocaine intake in a carefully controlled manner, using considerably less cocaine (about half) that permitted by pump loading, PCA parameters, and session duration. CONCLUSIONS: Data from this study support the validity of our PCA paradigm. Moreover, results suggest the apparent feasibility and safety of allowing experienced users to self-select the timing of cocaine infusions to intervals as short as 5 min. Such procedures may enhance our ability to identify effective pharmacological treatments for cocaine addiction.
RCT Entities:
INTRODUCTION: Current laboratory paradigms of humancocaine administration generally dictate the timing of drug access in ways that may limit assessing aspects of cocaine-taking behavior. Patient-controlled analgesia (PCA) methods, which allow individuals less restricted access to narcotic (i.e., opiate) analgesics, have proven safe and clinically effective for self-regulated treatment of pain. The current study assessed the feasibility, safety, and validity of a model of ad libitum cocaine self-administration, in which participants self-selected the timing of cocaine infusions, using PCA techniques. METHODS: Eight nontreatment seeking, otherwise medically healthy, experienced cocaine users participated in a double-blind, placebo-controlled, escalating-dose regimen of intravenous cocaine (0, 8, 16, and 32 mg per 70 kg) on 4 test days, during which time participants had 2 h of access to cocaine via manual presses of a corded PCA pump button under a fixed ratio 1: time-out 5-min schedule. RESULTS: Procedures were well-tolerated by participants, and no significant adverse events were noted. Measures of cocaine self-administration (e.g., number of responses and interinfusion intervals) indicated a significant main effect of cocaine dose, consistent with predicted dose-response relationships (i.e., decreasing responses and increasing interinfusion intervals with increasing injection dose). Participants appeared to regulate their cocaine intake in a carefully controlled manner, using considerably less cocaine (about half) that permitted by pump loading, PCA parameters, and session duration. CONCLUSIONS: Data from this study support the validity of our PCA paradigm. Moreover, results suggest the apparent feasibility and safety of allowing experienced users to self-select the timing of cocaine infusions to intervals as short as 5 min. Such procedures may enhance our ability to identify effective pharmacological treatments for cocaine addiction.
Authors: N D Volkow; G J Wang; M W Fischman; R W Foltin; J S Fowler; N N Abumrad; S Vitkun; J Logan; S J Gatley; N Pappas; R Hitzemann; C E Shea Journal: Nature Date: 1997-04-24 Impact factor: 49.962
Authors: James J Mahoney; Ari D Kalechstein; Richard De La Garza; Thomas F Newton Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2007-01-31 Impact factor: 5.067
Authors: Rasmon Kalayasiri; Joel Gelernter; Lindsay Farrer; Roger Weiss; Kathleen Brady; Ralitza Gueorguieva; Henry R Kranzler; Robert T Malison Journal: Drug Alcohol Depend Date: 2009-11-26 Impact factor: 4.492
Authors: D Matuskey; B Pittman; J I Chen; J Wanyiri; H Nadim; P Jatlow; R Gueorguieva; M N Potenza; P T Morgan; Z Bhagwagar; R T Malison Journal: Pharmacol Biochem Behav Date: 2012-11 Impact factor: 3.533
Authors: Gustavo A Angarita; Brian Pittman; Ralitza Gueorguieva; Rasmon Kalayasiri; Wendy J Lynch; Atapol Sughondhabirom; Peter T Morgan; Robert T Malison Journal: Pharmacol Biochem Behav Date: 2009-12-21 Impact factor: 3.533
Authors: Wendy J Lynch; Rasmon Kalayasiri; Atapol Sughondhabirom; Brian Pittman; Vladimir Coric; Peter T Morgan; Robert T Malison Journal: Addict Biol Date: 2008-09 Impact factor: 4.280